taladegib
Small moleculeexperimental
Clinical trial activity
11 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01681186)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Cholangiocarcinoma · Phase 1
- Colonic Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Idiopathic Pulmonary Fibrosis · Phase 2
- Lung Diseases · Phase 2
- Medulloblastoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 1/Phase 2
Mechanism of action
- Smoothened homologANTAGONIST
SMO antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1- Mol. weight
- 512.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2142592 ↗
Also known as
- ly2940680
- ly2940680
- ly-2940680
- ly-2940680
- taladegib
- taladegib
- taladegib
- taladegib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06422884 | Phase 2 | Sep 30, 2024 | Endeavor Biomedicines, Endeavor Biomedicines, Inc. |
| NCT05817240 | Phase 1 | May 3, 2023 | Endeavor Biomedicines, Endeavor Biomedicines, Inc. |
| NCT05199584 | Phase 2 | May 24, 2022 | Endeavor Biomedicines, Endeavor Biomedicines, Inc. |
| NCT04968574 | Phase 2 | Aug 31, 2021 | Endeavor Biomedicines, Endeavor Biomedicines, Inc. |
| NCT02530437 | Phase 1/Phase 2 (Phase 2) | Mar 7, 2017 | Eli Lilly, National Cancer Institute (NCI), University of Texas at Houston |
| NCT02784795 | Phase 1 | Nov 1, 2016 | Eli Lilly |
| NCT01919398 | Phase 1 | Aug 1, 2013 | Eli Lilly, Ignyta, Inc. |
| NCT01697514 | Phase 1 | Jul 1, 2013 | Eli Lilly |
| NCT01746745 | Phase 1 | Jan 1, 2013 | Eli Lilly |
| NCT01722292 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2013 | Eli Lilly |
| NCT01681186 | Phase 1 | Sep 1, 2012 | Eli Lilly |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 7 | 6 | 2 | 2012 |
| Endeavor Biomedicines | For profit | 4 | 0 | 2 | 2021 |
| Endeavor Biomedicines, Inc. | For profit | 4 | 4 | 2 | 2021 |
| Ignyta, Inc. | For profit | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2017 |
6 organizations
Page 1 / 1